SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Korecka M.)
 

Search: WFRF:(Korecka M.) > (2020-2023) > Validation of Plasm...

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

Li, Yan (author)
Washington University in St. Louis
Schindler, Suzanne E. (author)
Washington University in St. Louis
Bollinger, James G. (author)
Washington University in St. Louis
show more...
Ovod, Vitaliy (author)
Washington University in St. Louis
Mawuenyega, Kwasi G. (author)
Washington University in St. Louis
Weiner, Michael W. (author)
University of California, San Francisco
Shaw, Leslie M. (author)
University of Pennsylvania
Masters, Colin L. (author)
University of Melbourne
Fowler, Christopher J. (author)
University of Melbourne
Trojanowski, John Q. (author)
University of Pennsylvania
Korecka, Magdalena (author)
University of Pennsylvania
Martins, Ralph N. (author)
Edith Cowan University
Janelidze, Shorena (author)
Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
Hansson, Oskar (author)
Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital
Bateman, Randall J. (author)
Washington University in St. Louis
show less...
Washington University in St Louis University of California, San Francisco (creator_code:org_t)
2022
2022
English.
In: Neurology. - 0028-3878. ; 98:7, s. 688-699
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background and Objectives To determine the diagnostic accuracy of a plasma Aβ42/Aβ40 assay in classifying amyloid PET status across global research studies using samples collected by multiple centers that utilize different blood collection and processing protocols.MethodsPlasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), Australia (n = 183), and Sweden (n = 100). Plasma Aβ42/Aβ40 was measured by a high precision immunoprecipitation mass spectrometry (IPMS) assay and compared to the reference standards of amyloid PET and CSF Aβ42/Aβ40.ResultsIn the combined cohort of 465 participants, plasma Aβ42/Aβ40 had good concordance with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.80-0.87); concordance improved with the inclusion of APOE ϵ4 carrier status (AUC 0.88, 95% CI 0.85-0.91). The AUC of plasma Aβ42/Aβ40 with CSF amyloid status was 0.85 (95% CI 0.78-0.91) and improved to 0.93 (95% CI 0.89-0.97) with APOE ϵ4 status. These findings were consistent across the 3 cohorts, despite differences in protocols. The assay performed similarly in both cognitively unimpaired and impaired individuals.DiscussionPlasma Aβ42/Aβ40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials.Classification of EvidenceThis study provides Class II evidence that plasma Aβ42/Aβ40, as measured by a high precision IPMS assay, accurately diagnoses brain amyloidosis in both cognitively unimpaired and impaired research participants.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

  • Neurology (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view